



## Mithra announces changes within its Board of Directors

**Liege, Belgium, 6 July 2022 – 17:45 CET** – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces a change in its Board of Directors' Chairmanship. Following the resignation with immediate effect of Mr. Ajit Shetty for personal reasons nonrelated to the Company, the Board of Directors approved, on the proposal of the outgoing Chairman and the recommendation of the Nomination and Remuneration Committee, the appointment of Mr. Christian Moretti as Chairman, as well as that of Mr. Erik Van Den Eynden as Vice-Chairman. These functions will be exercised until the next Company's Shareholders Meeting in May 2023 called to deliberate on the renewal of the Board at the end of the members' terms of office.

As graduate of HEC Paris and Columbia Business School, Mr. Moretti worked for 10 years in the banking sector, before founding the industrial holding Dynaction listed on the Paris stock exchange. He then focused on the development of one of the holding's subsidiaries, PCAS Biosolution, which he managed as CEO for 13 years and enabled it to become the European leader in the chemistry of complex molecules, employing more than 1,000 people worldwide. In addition to his extensive experience in the financial and industrial fields, Mr. Moretti has a deep knowledge of Mithra's strategic and operational priorities, since he has been on its Board of Directors for more than 3 years. He will be assisted in his new function by Mr. Erik Van Den Eynden, who has more than 30 years of experience in the banking sector and who has served as an independent director on the Board of Directors of Mithra since November 2020.

**Ajit Shetty, outgoing Chairman of Mithra's Board of Directors, comments:** "It was a real honour to chair this Board of Directors which I have to leave before the end of my term for personal reasons. I have full confidence in the expertise of Mr. Moretti to ensure a committed Chairmanship alongside the other directors in place and will of course remain at their disposal to advise and support them on main strategic issues, in particular ongoing business negotiations related to Donesta®."

**Christian Moretti, new Chairman of Mithra's Board of Directors, adds:** "We can only feel privileged to have been able to count on such an experienced pharmaceutical personality as Mr. Shetty. His vision, his knowledge of the sector, his international network have enabled us to bring a new dimension to the Company. On behalf of the entire Board and Executive Management, we sincerely thank him for taking so much of his precious time to help Mithra grow during this phase of business development."

\*\*\*\*\*

### For more information, please contact:

**Benoît Mathieu (IRO) : +32 473 35 80 18 – [investorrelations@mithra.com](mailto:investorrelations@mithra.com)**  
**Maud Vanderthommen (Press) : +32 473 58 61 04 – [press@mithra.com](mailto:press@mithra.com)**

### About Mithra

*Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle®, Mithra is now focusing on its second product Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium.*  
[www.mithra.com](http://www.mithra.com)

*Donesta® is a registered trademark of Mithra Pharmaceuticals or one of its affiliates.*

### Important information

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*

News  
Alerts

Subscribe to our mailing list on [investors.mithra.com](http://investors.mithra.com) to receive our press releases by email or follow us on our social media :

[LinkedIn](#) • [Twitter](#) • [Facebook](#)